Central and Southern Asia vs Oman: Proportion of the target population who received a 3rd dose of
Central and Southern Asia
89.0%
in 2024
Oman
99.0%
in 2024
Central and Southern Asia rank
2nd
Oman rank
1st
Proportion of the target population who received a 3rd dose of over time
- Central and Southern Asia
- Oman
How they compare
Oman currently reports 99.0% against 89.0% in Central and Southern Asia, a difference of 10.0%.
That makes Oman's figure about 1.1 times Central and Southern Asia's.
Across all 13 years both countries report, Oman has been ahead every year.
Central and Southern Asia ranks 2nd and Oman ranks 1st of 37 groups.
Oman has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Central and Southern Asia | Oman | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 20.8% | 98.8% | 78.0% | Oman |
| 2020s | 65.4% | 98.6% | 33.2% | Oman |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher proportion of the target population who received a 3rd dose of, Central and Southern Asia or Oman?
- Oman, at 99.0% against 89.0% in Central and Southern Asia as of 2024.
- What is the difference in proportion of the target population who received a 3rd dose of between Central and Southern Asia and Oman?
- 10.0%, with Oman ahead.
- How many years of comparable data are there for Central and Southern Asia and Oman?
- 13 years are reported by both, from 2012 to 2024.
- How do Central and Southern Asia and Oman rank globally for proportion of the target population who received a 3rd dose of?
- Central and Southern Asia ranks 2nd and Oman ranks 1st of 37 groups.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Proportion of the target population who received a 3rd dose of pneumococcal conjugate (PCV3) vaccine (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.